NCCN Melanoma Guidelines: Staging and Follow-Up

Overview / Definition Melanoma is a malignant tumor derived from melanocytes, the pigment-producing cells found in the skin, eyes, and other tissues. It is one of the most aggressive forms of skin cancer, characterized by its ability to metastasize to distant sites. The NCCN Melanoma Guidelines serve as a crucial resource for clinicians in the accurate staging, treatment, and follow-up of melanoma patients. Epidemiology Melanoma is the seventh most common cancer in the United States, with an annual incidence of approximately 22 cases per 100,000 individuals. The disease is more prevalent in individuals with fair skin, especially those with a history of sun exposure or tanning bed use. Key epidemiological factors include: Age: Most frequently diagnosed in individuals aged 25-29 years. Gender: More common in men than women. Geographic Variation: Higher incidence rates in regions with intense sunlight exposure. Pathophysiology / Mechanism The pathophysiology of melanoma involves genetic mutations that lead to uncontrolled proliferation of melanocytes. Key mutations include: BRAF mutations: Present in approximately 40-60% of melanoma cases, leading to activation of the MAPK signaling pathway. NRAS mutations: Found in about 15-20% of cases. TP53 mutations: Often associated with more aggressive disease. Environmental factors, particularly ultraviolet (UV) radiation exposure, play a significant role in initiating these genetic changes. Clinical Presentation Melanoma can present in various forms, with the most common being: Superficial spreading melanoma: Typically presents as a flat or slightly elevated lesion with irregular borders. Nodular melanoma: Often appears as a dome-shaped, blue-black nodule. Lentigo maligna melanoma: Arises from a lentigo maligna, usually in sun-exposed areas. Acral lentiginous melanoma: Occurs on non-sun-exposed areas such as palms and soles, more common in darker-skinned individuals. Classic signs include the ABCDE criteria: Asymmetry, Border i